Teduglutide (Gattex)

FDA-approved product existsPeptideImmune & gut

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Teduglutide (Gattex)?

FDA-approved teduglutide is marketed as Gattex for adults and pediatric patients one year and older with short bowel syndrome who are dependent on parenteral support.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelGATTEX prescribing information for short bowel syndrome with dependence on parenteral support
PopulationAdults and pediatric patients one year and older covered by the approved GATTEX indication
Dose0.05 mg/kg once daily; the label specifies adjustments for pediatric patients weighing less than 10 kg and for moderate or severe renal impairment
RouteSubcutaneous injection, rotating among the four quadrants of the abdomen, thighs, and arms
FrequencyOnce daily
DurationLong-term use within the approved indication
PreparationReconstitute the 5 mg lyophilized single-dose vial using the supplied 0.5 mL Sterile Water for Injection. Gently roll the vial; do not shake. Use the reconstituted solution within 3 hours and discard unused portion.
Source: Dosage and Administration sections 2.1-2.3; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.